Concepedia

Hermann Fahrngruber

HF

Statistics

Publications

4

Citations

512

H-Index

4

Active since

1997

Affiliations

Novartis (Austria)(Current)

Novartis (Switzerland)

Hermann Fahrngruber is an author at Novartis (Austria) specializing in dermatology, inflammation, and medicine.

Publications per year

1997–2022

4

Publications

4

The Impact of Prolonged Inflammation on Wound Healing

Judith C. J. Holzer-Geissler, Simon Schwingenschuh, Martin Zacharias et al. · Biomedicines · 2022 · 195 citations · Full text

Veterinary Medicine, Immunology, Pathobiology +16

A novel anti-inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases:<i>in vivo</i>pharmacology

Josef G. Meingassner, M. A. Grassberger, Hermann Fahrngruber et al. · British Journal of Dermatology · 1997 · 179 citations

Medicine, Dermatology, Pharmacology +17

Inhibition of Chronic and Acute Skin Inflammation by Treatment with a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor

Cornelia Halin, Hermann Fahrngruber, Josef G. Meingassner et al. · American Journal Of Pathology · 2008 · 90 citations · Full text

Medicine, Dermatology, Pharmacology +12

Pimecrolimus Inhibits the Elicitation Phase but Does Not Suppress the Sensitization Phase in Murine Contact Hypersensitivity, in Contrast to Tacrolimus and Cyclosporine A11Results reported in part at the SID meeting 2000 in Chicago (Meingassner J, Fahnrgruber H, Bavandi A: SDZ ASM 981, in contrast to CyA and FK 509, does not suppress the primary immune response in murine allergic contact dermatitis. J Invest Dermatol 114:832, 2000).

Josef G. Meingassner, Hermann Fahrngruber, A. Bavandi · Journal of Investigative Dermatology · 2003 · 48 citations · Full text

Medicine, Dermatology, Pharmacology +17

1–4 of 4